Woodward Specialty

Woodward Specialty LLC is a commercial-stage specialty pharmaceutical company focused on the acquisition, licensing, and commercialization of branded and generic prescription drugs for the U.S. market. Operating as an affiliate of Future Pak, LLC, the company recently relocated its core strategic operations to Puerto Rico to leverage the region's robust bioscience infrastructure. Woodward Specialty manages a diverse portfolio across multiple therapeutic areas, including gastrointestinal health, oncology, and sleep medicine, highlighted by a significant 2026 licensing agreement for the exclusive U.S. rights to Jaguar Health's antidiarrheal products Mytesi and Canalevia-CA1. The company provides integrated pharmaceutical services, including supply chain management, quality assurance, and intellectual property management, to support the growth of its commercial platform.